نتایج جستجو برای: vaccine administration route

تعداد نتایج: 399116  

2011
Byoung-Shik Shim Young Ki Choi Cheol-Heui Yun Eu-Gene Lee Yoon Seong Jeon Sung-Moo Park In Su Cheon Dong-Hyun Joo Chung Hwan Cho Min-Suk Song Sang-Uk Seo Young-Ho Byun Hae-Jung Park Haryoung Poo Baik Lin Seong Jae Ouk Kim Huan Huu Nguyen Konrad Stadler Dong Wook Kim Kee-Jong Hong Cecil Czerkinsky Man Ki Song

BACKGROUND The ectodomain of matrix protein 2 (M2e) of influenza A virus is a rationale target antigen candidate for the development of a universal vaccine against influenza as M2e undergoes little sequence variation amongst human influenza A strains. Vaccine-induced M2e-specific antibodies (Abs) have been shown to display significant cross-protective activity in animal models. M2e-based vaccin...

2017
Rasmus Mortensen Dennis Christensen Lasse Bøllehuus Hansen Jan Pravsgaard Christensen Peter Andersen Jes Dietrich

Streptococcus pyogenes (group A streptococcus, GAS) is responsible for a wide array of infections. Respiratory transmission via droplets is the most common mode of transmission but it may also infect the host via other routes such as lesions in the skin. To advance the development of a future vaccine against GAS, it is therefore important to investigate how protective immunity is related to the...

2013
Alicia Martinez-Lopez Pablo García-Valtanen María del Mar Ortega-Villaizan Verónica Chico Regla María Medina-Gali Luis Perez Julio Coll Amparo Estepa

The route of administration of DNA vaccines can play a key role in the magnitude and quality of the immune response triggered after their administration. DNA vaccines containing the gene of the membrane-anchored glycoprotein (gpG) of the fish rhabdoviruses infectious haematopoietic necrosis virus (IHNV) or viral haematopoietic septicaemia virus (VHSV), perhaps the most effective DNA vaccines ge...

Journal: : 2021

Registration and analysis of adverse events following immunisation (AEFIs) allow for objective assessment systematisation AEFI causes, promotion vaccination safety. Development abscesses after DTP is a fairly common AEFI, however, they are not included in the “Side effects” part patient information leaflet vaccine. The aim study was to analyse reasons abscess development elaborate recommendatio...

Journal: :Hong Kong medical journal = Xianggang yi xue za zhi 2005
S S Y Wong K Y Yuen

Currently available vaccines have similar efficacy if they are matched to the most prevalent circulating strains. They also have comparable adverse effect profiles. The choice of a specific preparation of vaccine therefore requires consideration of cost, purity of the vaccine preparation in terms of the amount of egg protein and endotoxin, allergy to different constituents of the vaccine, react...

Journal: :Infection and immunity 2007
Easwaran Ravichandran Fetweh H Al-Saleem Denise M Ancharski Mohammad D Elias Ajay K Singh Mohammad Shamim Yujing Gong Lance L Simpson

Most reports dealing with vaccines against botulinum toxin have focused on the injection route of administration. This is unfortunate, because a mucosal vaccine is likely to be more efficacious for patients and pose fewer risks to health care workers and to the environment. Therefore, efforts were made to generate a mucosal vaccine that provides protection against the botulinum serotypes that t...

Journal: :Infection and immunity 2008
Si Ying Ho Shi Qian Chua Damian G W Foo Camille Locht Vincent T Chow Chit Laa Poh Sylvie Alonso

Bordetella pertussis, the causative agent of whooping cough, is a promising and attractive candidate for vaccine delivery via the nasal route, provided that suitable attenuation of this pathogen has been obtained. Recently, the highly attenuated B. pertussis BPZE1 strain has been described as a potential live pertussis vaccine for humans. We investigated here the use of BPZE1 as a live vehicle ...

Journal: :Vaccine 2011
A I Camacho J de Souza S Sánchez-Gómez M Pardo-Ros J M Irache C Gamazo

Vaccination appears to be the only rational prophylactic approach to control shigellosis. Unfortunately, there is still no safe and efficacious vaccine available. We investigated the protection conferred by a new vaccine containing outer membrane vesicles (OMVs) from Shigella flexneri with an adjuvant based on nanoparticles in an experimental model of shigellosis in mice. OMVs were encapsulated...

Journal: :Infection and immunity 2009
Ankan Gupta Nishamol Geetha Jiju Mani Pramod Upadhyay V M Katoch M Natrajan U D Gupta Sangeeta Bhaskar

As the disease caused by Mycobacterium tuberculosis continues to be a burden, there is a concerted effort to find new vaccines to combat this problem. One of the important vaccine strategies is whole bacterial vaccines. This approach relies on multiple antigens and built-in adjuvanticity. Other mycobacterial strains which share cross-reactive antigens with M. tuberculosis have been considered a...

Journal: :Health affairs 2011
Lewellys F Barker Annmarie E Leadman Bartholt Clagett

The World Health Organization estimates that tuberculosis is causing nearly two million deaths annually, mostly in developing countries. Widespread administration of the current tuberculosis vaccine to newborns is not a reliable route for preventing the disease in adults, the population that drives the epidemic. Several new vaccine candidates are in development, and a few have entered clinical ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید